Open AccessEarly serum albumin changes in patients with ulcerative colitis treated with tacrolimus will predict clinical outcome
Author(s) -
Natsuki Ishida,
Takahiro Miyazu,
Satoshi Tamura,
Shinya Tani,
Mihoko Yamade,
Moriya Iwaizumi,
Yasushi Hamaya,
Satoshi Osawa,
Takahisa Furuta,
Ken Sugimoto
Publication year - 2021
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v27.i22.3109
Subject(s) - ulcerative colitis , tacrolimus , medicine , gastroenterology , albumin , serum albumin , colitis , calcineurin , colectomy , transplantation , disease
Oral tacrolimus is a therapeutic agent for moderate to severe steroid-dependent or resistant ulcerative colitis (UC), but remission induction is difficult, and it is necessary to treat the patient while considering the next treatment.